Europe – MHRA Blocks 135 Drugs From Parallel Export

As drug shortage questions and increasing demands loom amid the coronvirus pandemic, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) this month added 135 medicines to its list of medicines that cannot be parallel exported from the UK.

Parallel exporting means buying medicines already on the market in the UK and selling them in another country in the European Economic Area.

Beginning on 13 March, MHRA added hydroxychloroquine, a possible COVID-19 treatment, to its list, and then a week later, MHRA added 82 more medicines, including the antibiotics amoxicillin and levofloxacin, as well as the pain drugs oxycodone and fentanyl, and other common medicines like paracetamol and insulin…